Neuralstem Announces the Appointment of Two New Members to the Board of Directors
September 25 2017 - 4:05PM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that Zhang Zhuo and Cristina Csimma, PharmD, MHP, have
been appointed to its Board of Directors, effective September 18,
2017.
“I’m very pleased to welcome Mr. Zhang and Dr. Csimma to our
Board,” said Rich Daly, Chairman and CEO. “Mr. Zhang joins us as
Tianjin Pharmaceuticals’ appointee as agreed to in connection with
their $20 million strategic investment in December of 2016. We very
much value the support Tianjin has provided in the past year, and
look forward to working with such a major multinational
pharmaceutical enterprise further on the research and development
of our innovative stem cell and small molecule platforms.”
“Dr. Csimma brings with her decades of senior leadership
experience in the biopharmaceutical industry as well as a wealth of
expertise in drug development. Her insights into corporate
operations and capital raising will be immensely helpful to
Neuralstem during this potentially transformative period for the
company,” Mr. Daly continued.
Mr. Zhang is currently the Vice Director of International
Cooperation for Tianjin Pharmaceuticals, which he joined in 2011.
Mr. Zhang holds a Master of Science from the London School of
Economics and Political Science, and a Bachelor of Commerce in
Economics and International Business from the University of
Auckland, New Zealand.
Cristina Csimma is the Executive Chair, Board of Directors for
Exonics Therapeutics and is also a Board Member and Member of the
Compensation and Nominating and Corporate Governance Committees of
Juniper Pharmaceuticals. She also serves on advisory boards
including Sucampo Pharmaceuticals, the Muscular Dystrophy
Association Venture Philanthropy Scientific Advisory Committee; the
Executive Oversight Board to the National Institutes of Health
(NIH) NeuroNext Network; the External Oversight Committee of NIH
Blueprint Neurotherapeutics Network, the Harvard and Brigham and
Women’s Hospital MRCT Center External Advisory Board, the
Rockefeller University Robertson Therapeutic Development Fund
Review Committee and the TREAT-NMD Advisory Committee for
Therapeutics (TACT). She was previously a Board Director of Vtesse
(acquired in March 2017 by Sucampo Pharmaceuticals) and Cydan,
where she was also President and founding CEO, the Vice President
of Drug Development at Virdante Pharmaceuticals Inc (acquired by
Moderna), Principal at Clarus Ventures LLC, and held roles in
Clinical Development and Translational Research at Wyeth (now
Pfizer), Genetics Institute and Dana Farber Cancer Institute.
Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of
Science in Pharmacy from the Massachusetts College of Pharmacy and
Allied Health Sciences, as well as a Master of Health Professions
from Northeastern University.
About Neuralstem Neuralstem is a clinical-stage
biopharmaceutical company developing novel treatments for nervous
system diseases of high unmet medical need. NSI-189 is a
small molecule in clinical development for major depressive
disorder (MDD) and in preclinical development for Angelman
syndrome, irradiation-induced cognitive impairment, Type 1 and Type
2 diabetes, and stroke.
NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, chronic spinal cord injury (cSCI) and
Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified
portfolio of product candidates is based on its proprietary neural
stem cell technology.
Cautionary Statement Regarding Forward Looking
InformationThis news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three and six
months ended June 30, 2017, filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do
not assume any obligation to update any forward-looking
statements.
Contact:
Kimberly MinarovichArgot Partners (Investor
Relations)212-600-1902kimberly@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024